The challenges of ‘orphan’: can drug development cope with rare diseases?
Scarcely a day goes by that the Clinuvel team is not contacted regarding the latest conference: everything from monitoring to manufacturing to marketing is analysed, discussed and disputed across the...
View ArticleA clinical success: study retention rates
We were delighted this week to be able to announce the successful completion of our first Phase II study conducted in the US, a placebo controlled, randomised trial of SCENESSE® (afamelanotide) for...
View ArticleVitiligo, light therapy and stem cells: a new webcast online
Vitiligo Narrowband UVB treatment Today we’ve released our first new video webcast for the year, explaining the theory of repigmentation in vitiligo with narrowband UVB (NB-UVB) phototherapy in greater...
View ArticleA new program for SCENESSE®: nonsegmental vitiligo
A patient with vitiliginous lesions on their fingers and hands Today Clinuvel has announced that it will be commencing a new program for SCENESSE® in the common pigmentary disorder vitiligo. While...
View ArticleUnder your skin: Sunscreen and skin cancer this summer
With the northern Hemisphere officially creeping into summer, the first arguments of this season’s sun and skin debate have arisen Anti cancer councils and organisations akin to Australia’s Sunsmart...
View ArticleBroader implications of a landmark announcement
I take a moment on this day to discuss a separate impact of the surprising development surrounding our photoprotective drug afamelanotide, despite this being a result where Clinuvel has not played any...
View ArticleUnexpected news for afamelanotide from Italy
An unprecedented and unexpected announcement over the weekend has lead to the company’s announcement this morning that afamelanotide will be first made available to Italian erythropoietic...
View ArticleIntroduction to the melanocortin system
The body consists of cells which communicate with each other via signaling molecules to govern and determine a variety of physiological functions in the body. The action and effect of these signaling...
View ArticleThe fear of what lay ahead
“The fear of what lay ahead” is our latest webcast exploring the impact of EPP upon individuals, their families and loved ones. Wendy and Ralph are the proud parents of two daughters, who were both...
View ArticleTalking off the label – part three
Allergan’s lawsuit filed against the FDA presents a relatively novel case in addressing the requirements of drug developers in relation to off-label use of drugs by physicians. Allergan may be one of...
View Article